Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel R Kennedy

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
American Journal of Pharmaceutical Education|July 9, 2023
The AACP Academic Affairs Committee's Guidance for Use of the Curricular Outcomes and Entrustable Professional Activities (COEPA) for Pharmacy GraduatesMelissa S Medina, Michelle Z Farland, John M Conry, et al.
Frontiers in Immunology|January 8, 2021
Protein Disulfide Isomerases Regulate IgE-Mediated Mast Cell Responses and Their Inhibition Confers Protective Effects During Food AllergyDylan Krajewski, Stephanie H Polukort, Justine Gelzinis, et al.
American Journal of Pharmaceutical Education|February 13, 2023
Revising the Center for the Advancement of Pharmacy Education (CAPE) Educational Outcomes and Entrustable Professional Activities (EPAs): The Report of the 2021-2022 Academic Affairs Standing CommitteeMelissa Medina, Scott Stolte, John Conry, et al.
British Journal of Pharmacology|October 20, 2020
Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding timesLisa-Marie Holbrook, Shirley J Keeton, Parvathy Sasikumar, et al.
American Journal of Pharmaceutical Education|July 9, 2023
The AACP Academic Affairs Committee's Final 2022 Curricular Outcomes and Entrustable Professional Activities (COEPA) for Pharmacy Graduates to Replace 2013 CAPE and 2016 EPAsMelissa S Medina, Michelle Z Farland, John M Conry, et al.
Journal of Medical Devices|May 3, 2018
A Novel Macroscale Acoustic Device for Blood FiltrationBrian Dutra, Maria Carmen Mora, Tyler I Gerhardson, et al.
The Journal of Clinical Investigation|May 9, 2012
Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agentsReema Jasuja, Freda H Passam, Daniel R Kennedy, et al.
Nature Communications|August 31, 2016
A substrate-driven allosteric switch that enhances PDI catalytic activityRoelof H Bekendam, Pavan K Bendapudi, Lin Lin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 20, 2025
Development of Zafirlukast Analogues for Improved Antithrombotic Activity Through Thiol Isomerase InhibitionJustine A Keovilay, Kaitlind C Howard, Kirk A Taylor, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 12, 2023
Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinicJustine A Gelzinis, Melanie K Szahaj, Roelof H Bekendam, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
American Journal of Pharmaceutical Education|July 9, 2023
The AACP Academic Affairs Committee's Guidance for Use of the Curricular Outcomes and Entrustable Professional Activities (COEPA) for Pharmacy GraduatesMelissa S Medina, Michelle Z Farland, John M Conry, et al.
Frontiers in Immunology|January 8, 2021
Protein Disulfide Isomerases Regulate IgE-Mediated Mast Cell Responses and Their Inhibition Confers Protective Effects During Food AllergyDylan Krajewski, Stephanie H Polukort, Justine Gelzinis, et al.
American Journal of Pharmaceutical Education|February 13, 2023
Revising the Center for the Advancement of Pharmacy Education (CAPE) Educational Outcomes and Entrustable Professional Activities (EPAs): The Report of the 2021-2022 Academic Affairs Standing CommitteeMelissa Medina, Scott Stolte, John Conry, et al.
British Journal of Pharmacology|October 20, 2020
Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding timesLisa-Marie Holbrook, Shirley J Keeton, Parvathy Sasikumar, et al.
American Journal of Pharmaceutical Education|July 9, 2023
The AACP Academic Affairs Committee's Final 2022 Curricular Outcomes and Entrustable Professional Activities (COEPA) for Pharmacy Graduates to Replace 2013 CAPE and 2016 EPAsMelissa S Medina, Michelle Z Farland, John M Conry, et al.
Journal of Medical Devices|May 3, 2018
A Novel Macroscale Acoustic Device for Blood FiltrationBrian Dutra, Maria Carmen Mora, Tyler I Gerhardson, et al.
The Journal of Clinical Investigation|May 9, 2012
Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agentsReema Jasuja, Freda H Passam, Daniel R Kennedy, et al.
Nature Communications|August 31, 2016
A substrate-driven allosteric switch that enhances PDI catalytic activityRoelof H Bekendam, Pavan K Bendapudi, Lin Lin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 20, 2025
Development of Zafirlukast Analogues for Improved Antithrombotic Activity Through Thiol Isomerase InhibitionJustine A Keovilay, Kaitlind C Howard, Kirk A Taylor, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 12, 2023
Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinicJustine A Gelzinis, Melanie K Szahaj, Roelof H Bekendam, et al.
Pageof 4